[go: up one dir, main page]

PT81589A - Process for the preparation of tricyclo compounds useful for treating and preventing resistence by transplantation and other diseases - Google Patents

Process for the preparation of tricyclo compounds useful for treating and preventing resistence by transplantation and other diseases

Info

Publication number
PT81589A
PT81589A PT81589A PT8158985A PT81589A PT 81589 A PT81589 A PT 81589A PT 81589 A PT81589 A PT 81589A PT 8158985 A PT8158985 A PT 8158985A PT 81589 A PT81589 A PT 81589A
Authority
PT
Portugal
Prior art keywords
diseases
transplantation
compounds useful
resistence
treating
Prior art date
Application number
PT81589A
Other languages
English (en)
Other versions
PT81589B (pt
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430455A external-priority patent/GB8430455D0/en
Priority claimed from GB858502869A external-priority patent/GB8502869D0/en
Priority claimed from GB858508420A external-priority patent/GB8508420D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT81589A publication Critical patent/PT81589A/pt
Publication of PT81589B publication Critical patent/PT81589B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/55—Streptomyces hygroscopicus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT81589A 1984-12-03 1985-12-02 Processo para a preparacao de compostos triciclo uteis para tratamento e prevencao de resistencia por transplantacao e outras doencas PT81589B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848430455A GB8430455D0 (en) 1984-12-03 1984-12-03 Fr-900506 substance
GB858502869A GB8502869D0 (en) 1985-02-05 1985-02-05 Ws 7238 substances
GB858508420A GB8508420D0 (en) 1985-04-01 1985-04-01 Fr-900506 & fr-900525 substances

Publications (2)

Publication Number Publication Date
PT81589A true PT81589A (en) 1986-01-01
PT81589B PT81589B (pt) 1987-10-20

Family

ID=27262535

Family Applications (1)

Application Number Title Priority Date Filing Date
PT81589A PT81589B (pt) 1984-12-03 1985-12-02 Processo para a preparacao de compostos triciclo uteis para tratamento e prevencao de resistencia por transplantacao e outras doencas

Country Status (24)

Country Link
US (15) US4894366A (pt)
EP (1) EP0184162B1 (pt)
JP (6) JPH0720970B2 (pt)
KR (5) KR930010704B1 (pt)
CN (1) CN1013687B (pt)
AT (1) ATE104984T1 (pt)
AU (1) AU592067B2 (pt)
CA (1) CA1338491C (pt)
CY (1) CY1912A (pt)
DE (2) DE19575026I2 (pt)
DK (1) DK169550B1 (pt)
ES (1) ES8705038A1 (pt)
FI (2) FI87803C (pt)
GR (1) GR852904B (pt)
HK (1) HK18596A (pt)
HU (1) HU195250B (pt)
IE (1) IE62865B1 (pt)
IL (2) IL92345A (pt)
LU (1) LU90317I2 (pt)
MX (1) MX9202943A (pt)
NL (1) NL960023I2 (pt)
NO (1) NO168372C (pt)
NZ (1) NZ214407A (pt)
PT (1) PT81589B (pt)

Families Citing this family (317)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
EP0293892B1 (en) * 1987-06-05 1993-12-15 Fujisawa Pharmaceutical Co., Ltd. Anti-FR-900506 substance antibodies and highly-sensitive enzyme immunoassay method
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
CH677448A5 (pt) * 1987-11-09 1991-05-31 Sandoz Ag
DE3838035C2 (de) * 1987-11-09 1994-03-24 Sandoz Ag Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.OĀ·4Ā·Ā·,Ā·Ā·9Ā·]octacos-18-en-Derivaten
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
DE3844904C2 (de) * 1987-11-09 1997-01-30 Sandoz Ag Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0Ā·4Ā·,Ā·9Ā·]octacos-18-en-Derivaten
AT400808B (de) * 1987-11-09 1996-03-25 Sandoz Ag Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
AU630866B2 (en) 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds
AT407957B (de) * 1987-12-17 2001-07-25 Novartis Erfind Verwalt Gmbh Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
EP0323865A1 (en) * 1988-01-07 1989-07-12 Merck & Co. Inc. Novel immunosuppressant agent
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
EP0349061B1 (en) * 1988-06-29 1995-03-29 Merck & Co. Inc. Immunosuppressant agent
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
DE68925080T2 (de) * 1988-08-01 1996-05-15 Fujisawa Pharmaceutical Co FR-901154- und FR-901155-Derivate, Verfahren zu ihrer Herstellung
US5202258A (en) * 1988-08-05 1993-04-13 Merck & Co., Inc. Immunosuppressant-producing culture
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0358508A3 (en) * 1988-09-08 1991-03-20 Merck & Co. Inc. Novel immunosuppressant compound
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
DE68904037T2 (de) * 1988-10-12 1993-06-03 Merck & Co Inc Verfahren zur umlagerung von fk-506 unter beteiligung von hydroxid.
US4980466A (en) * 1988-10-12 1990-12-25 Merck & Co., Inc. Hydroxide mediated FK-506 rearrangement product
CH678855A5 (pt) * 1988-11-29 1991-11-15 Sandoz Ag
EP0378320A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product
EP0378317A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product of l-679,934
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
EP0388153B1 (en) * 1989-03-15 1994-12-28 Merck & Co. Inc. Immunosuppressant agent
US5272068A (en) * 1989-03-15 1993-12-21 Merck & Co., Inc. Process for producing immunosuppressant agent L-683942 by fermentation
DE69013189T2 (de) * 1989-03-15 1995-05-11 Merck & Co Inc Verfahren zur Herstellung einer immunosuppressiven Substanz (demethimmunomycin) durch Verwendung eines Stamm-Mutanten eines Mikroorganismus.
US4940797A (en) * 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
US5155228A (en) * 1989-03-23 1992-10-13 Merck & Co., Inc. FK-506 C10-C18 process intermediates
EP0399579A1 (en) * 1989-04-21 1990-11-28 Merck & Co. Inc. Macrolides having immunosuppressive activity
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5057608A (en) * 1989-04-21 1991-10-15 Merck & Co., Inc. Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
JPH0368583A (ja) * 1989-05-05 1991-03-25 Merck & Co Inc ę–°č¦å¾®ē”Ÿē‰©å¤‰ę›ē‰©č³Ŗ
US5270187A (en) * 1989-05-05 1993-12-14 Merck & Co., Inc. Microbial transformation product
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
CA2018710A1 (en) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683,590 microbial transformation product
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
KR920700212A (ko) * 1989-06-14 1992-02-19 ģŸ ķ¬ė¼ėØøĀ·ķ•œģŠ¤ ė£ØėŒķ”„ ķ•˜ģš°ģŠ¤ ķ—¤ķ…Œė”œģ›ģž-ķ•Øģœ  ķŠøė¦¬ģ‚¬ģ“ķ“ė¦­ ķ™”ķ•©ė¬¼
US5235066A (en) * 1989-06-30 1993-08-10 Merck & Co., Inc. FK-506 type macrolide intermediate
US5164525A (en) * 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
EP0487593A1 (en) * 1989-08-18 1992-06-03 FISONS plc Macrocyclic compounds
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
US5011943A (en) * 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc ĪĪ­Ī±Ī¹ Ī¼Ī±ĪŗĻĪæĪŗĻ…ĪŗĪ»Ī¹ĪŗĪ±ĪÆ ĪµĪ½ĻŽĻƒĪµĪ¹Ļ‚ ĪŗĪ±Ī¹ Ī½Ī­Ī± Ī¼Ī­?ĪæĪ“ĪæĻ‚ Ļ‡ĻĪ®ĻƒĪµĻ‰Ļ‚ Ļ„ĪæĻ…Ļ‚.
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressiveĀ¹activity
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
JPH05504956A (ja) * 1990-03-12 1993-07-29 č—¤ę²¢č–¬å“å·„ę„­ę Ŗ式会ē¤¾ 惈ćƒŖć‚·ć‚Æćƒ­åŒ–åˆē‰©
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
CA2040551A1 (en) * 1990-04-30 1991-10-31 Mark T. Goulet Deoxymacrolide derivatives having immunosuppressive activity
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
WO1991019495A1 (en) * 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
EP0466365A3 (en) * 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
EP0543879A1 (en) * 1990-08-18 1993-06-02 FISONS plc Macrocyclic compounds
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (en) * 1990-10-29 1992-04-30 Kevin M. Byrne Process for the production of analogues of immunomycin
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US5116756A (en) * 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
ATE198708T1 (de) * 1991-04-26 2001-02-15 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
EP0528452A1 (en) * 1991-06-19 1993-02-24 Merck & Co. Inc. Immunomycin enzymatic and/or microbial methylation products
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
DK0642516T3 (da) * 1991-09-05 2002-09-09 Abbott Lab Makrocykliske immunmodulatorer
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
CA2128790A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas Use of a compound for the manufacture of a medicament for the treatment of hiv infection
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼č£½č–¬ę Ŗ式会ē¤¾ ę–°č¦ćŖ大ē’°ēŠ¶ćƒ©ć‚Æćƒˆćƒ³ćŠć‚ˆć³ćć®ē”Ÿē”£čŒ
US5631235A (en) * 1992-03-02 1997-05-20 Pfizer, Inc. 2-Aminosugar derivatives of macrolides
JP2563080B2 (ja) * 1992-03-02 1996-12-11 ćƒ•ć‚¢ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒ„ćƒ‰ 惞ć‚Æćƒ­ćƒ©ć‚¤ćƒ‰ć®ē³–čŖ˜å°Žä½“
JP2564765B2 (ja) * 1992-03-02 1996-12-18 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ 惞ć‚Æćƒ­ćƒ©ć‚¤ćƒ‰ē³»ęŠ—ē”Ÿē‰©č³Ŗć®ćƒ•ćƒ«ć‚Ŗ惭ē³–čŖ˜å°Žä½“
EP0629203B1 (en) * 1992-03-02 2001-09-12 Pfizer Inc. Desosamino derivatives of macrolides as immunosuppressants and antifungal agents
DK0562853T3 (da) 1992-03-27 1996-07-01 American Home Prod 29-Demethoxyrapamycin til fremkaldelse af immunsuppression
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5324644A (en) * 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
DK0672756T3 (da) * 1992-08-12 2002-03-25 Fujisawa Pharmaceutical Co Monoklonalt antistof, som genkender FK506-bindende protein, fremgangsmƄde til mƄling af niveauet af FK506-bindende protein og kit dertil
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
DE4300478C2 (de) * 1993-01-11 1998-05-20 Eos Electro Optical Syst Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
WO1994021254A1 (en) * 1993-03-17 1994-09-29 Abbott Laboratories Substituted alicyclic amine-containing macrocyclic immunomodulators
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ćƒ­ćƒ¼ć‚·ćƒ§ćƒ³å‰¤
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
JPH09501162A (ja) * 1993-07-30 1997-02-04 ć‚¢ćƒœćƒ„ćƒˆćƒ»ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ 免ē–«čŖæēÆ€ę“»ę€§ć‚’ęœ‰ć™ć‚‹ę“»ę€§åŒ–ćƒžć‚Æ惭惩ć‚Æć‚æ惠
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
UA41884C2 (uk) * 1993-11-05 2001-10-15 ŠŠ¼ŠµŃ€Ń–ŠŗŠ°Š½ Š„Š¾ŃƒŠ¼ ŠŸŃ€Š¾Š“Š°Šŗтс ŠšŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹ŃˆŠ½ Š”ŠæŠ¾ŃŃ–Š± Š²Ń–Š“Š¾ŠŗрŠµŠ¼Š»ŠµŠ½Š½Ń рŠ°ŠæŠ°Š¼Ń–цŠøŠ½Ńƒ Š²Ń–Š“ ŠŗŠøсŠ»Š¾Ń‚Š½Šøх, Š¾ŃŠ½Š¾Š²Š½Šøх тŠ° Š½ŠµŠæŠ¾Š»ŃŃ€Š½Šøх Š½ŠµŠ¹Ń‚Ń€Š°Š»ŃŒŠ½Šøх Š“Š¾Š¼Ń–ŃˆŠ¾Šŗ, ŠæрŠøсутŠ½Ń–Ń… Š² ŠŗŠ¾Š½Ń†ŠµŠ½Ń‚Ń€Š°Ń‚Ń– ŠµŠŗстрŠ°ŠŗтіŠ² фŠµŃ€Š¼ŠµŠ½Ń‚Š°Ń†Ń–Š¹Š½Š¾Š³Š¾ Š±ŃƒŠ»ŃŒŠ¹Š¾Š½Ńƒ Š°Š±Š¾ Š¼Š°Ń‚Š¾Ń‡Š½Šøх рŠ¾Š·Ń‡ŠøŠ½Ń–Š²
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
PT786986E (pt) 1994-10-26 2002-07-31 Novartis Ag Formulacoes farmaceuticas
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
CN1137680C (zh) * 1995-09-19 2004-02-11 č—¤ę³½čÆ品巄äøšę Ŗ式会ē¤¾ ę°”é›¾å‰‚ē»„合ē‰©
ES2182112T3 (es) 1996-07-30 2003-03-01 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
KR100244164B1 (ko) * 1997-07-15 2000-03-02 ź¹€ģš©ģ˜„ ģˆ˜ģš©ģ„± ź³ ė¶„ģž-ķƒ€ķ¬ė”œė¦¬ė¬“ģŠ¤ ģ ‘ķ•©ģ²“ ķ™”ķ•©ė¬¼ ė° ź·øģ˜ ģ œģ”° ė°©ė²•
US6562620B2 (en) * 1997-09-19 2003-05-13 Mcgill University Medium to promote islet cell survival
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
ATE269075T1 (de) 1998-03-26 2004-07-15 Fujisawa Pharmaceutical Co Makrolid-formulierung mit verzƶgerter wirkstoffabgabe
ES2284248T3 (es) * 1998-04-27 2007-11-01 Astellas Pharma Inc. Formulacion farmaceutica en gel que comprende un compuesto triciclico (fk-506/tacrolimus).
BR9912423A (pt) 1998-07-17 2001-06-05 Agouron Pharmaceticals Inc Compostos e/ou derivados farmaceuticamente aceitĆ”veis, composiƧƵes farmacĆŖuticas, mĆ©todos de tratamento das disordens neurolĆ³gicas em pacientes e processos de preparaĆ§Ć£o dos compostos ou derivados farmaceuticamente aceitĆ”veis
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
IL142165A0 (en) 1998-10-02 2002-03-10 Kosan Biosciences Inc Polyketide synthase enzymes and recombinant dna constructs therefor
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
JP2002540211A (ja) * 1999-03-31 2002-11-26 ć‚¢ćƒœćƒƒćƒˆćƒ»ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ ćƒ•ć‚©ć‚¹ćƒ•ć‚§ćƒ¼ćƒˆå«ęœ‰å¤§ē’°å…ē–«čŖæēÆ€č–¬
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
DE60042425D1 (de) 1999-04-30 2009-07-30 Univ Michigan Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, EntzĆ¼ndungen, Neoplasien, viralen Infektionen und Atherosklerosis
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) * 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva GyĆ³gyszergyĆ”r ZĆ”rtkƶrĆ¼en MĆ¼kƶdƶ RĆ©szvĆ©nytĆ”rsasĆ”g Method for extracting a macrolide from biomatter
CA2475383C (en) * 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
BR0307788A (pt) * 2002-02-22 2006-04-04 3M Innovative Properties Co mĆ©todo de reduĆ§Ć£o e tratamento de imunossupressĆ£o induzida por uv-b
WO2004003214A1 (en) * 2002-06-28 2004-01-08 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
BR0314013A (pt) 2002-09-06 2005-07-12 Abbott Lab Equipamento mĆ©dico contendo inibidor de hidrataĆ§Ć£o
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004069845A1 (en) * 2003-02-10 2004-08-19 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
DE04758730T1 (de) * 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
WO2005010015A1 (en) * 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
US20070038289A1 (en) * 2003-08-05 2007-02-15 Kaneka Corporation Stent to be placed in vivo
PL1663217T3 (pl) 2003-08-29 2010-12-31 Lifecycle Pharma As Stałe dyspersje zawierające takrolimus
CN1859909B (zh) 2003-08-29 2011-04-06 ē”Ÿå‘½å‘ØꜟčÆē‰©å…¬åø å«ęœ‰ä»–å…‹čŽ«åøēš„å›ŗę€åˆ†ę•£ä½“
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
ES2317066T3 (es) * 2003-10-17 2009-04-16 Ranbaxy Laboratories Limited Produccion de tacrolimus (fk-506)utilizando nuevas especies de streptomyces.
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
CA2548297C (en) * 2003-12-05 2011-06-14 Biocon Limited Process for the purification of macrolides
KR100485877B1 (ko) * 2003-12-30 2005-04-28 ģ¢…ź·¼ė‹¹ė°”ģ“ģ˜¤ ģ£¼ģ‹ķšŒģ‚¬ ķƒ€ķ¬ė”¤ė¦¬ė¬“ģŠ¤ė„¼ ģƒģ‚°ķ•˜ėŠ” ėÆøģƒė¬¼ ė° ģ“ė„¼ ģ“ģš©ķ•œķƒ€ķ¬ė”¤ė¦¬ė¬“ģŠ¤ģ˜ ėŒ€ėŸ‰ ģƒģ‚°ė°©ė²•
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
WO2005089855A1 (en) 2004-03-19 2005-09-29 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
CA2562805C (en) 2004-04-12 2014-03-11 Biocon Limited Process for the production of macrolides using a novel strain, streptomyces sp. bicc 7522
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2006014722A (ja) 2004-06-02 2006-01-19 Keio Gijuku éŗä¼å­ćƒžćƒ¼ć‚«ćƒ¼åŠć³ćć®åˆ©ē”Ø
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US7534449B2 (en) * 2004-07-01 2009-05-19 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1786915A1 (en) * 2004-09-10 2007-05-23 Ivax Pharmaceuticals S.R.O. Process for isolation of crystalline tacrolimus
KR20070057915A (ko) * 2004-09-10 2007-06-07 ģ•„ģ“ė°•ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ»¬ģŠ¤ ģ—ģŠ¤.ģ•Œ.ģ˜¤. ė§¤ķ¬ė”¤ė¼ģ“ė“œ ķ™”ķ•©ė¬¼ģ˜ ė‹Øė¦¬ ė°©ė²•
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
ITMI20042098A1 (it) * 2004-11-03 2005-02-03 Antibioticos Spa Processo per la purificazione di tacrolimus
WO2006060617A1 (en) 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Ascomycin crystalline forms and preparation thereof
AU2005316473B2 (en) * 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
TW200637835A (en) * 2004-12-22 2006-11-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method of purifying tacrolimus
JP2008528448A (ja) * 2005-01-03 2008-07-31 悶 ćƒŖćƒ¼ć‚øć‚§ćƒ³ćƒ„ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ćƒŸć‚·ć‚¬ćƒ³ ę–°č¦åŒ–åˆē‰©ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•ć€ćŖć‚‰ć³ć«ćć®ęؙēš„
CA2588480A1 (en) * 2005-01-05 2006-08-10 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous tacrolimus and preparation thereof
ATE532064T1 (de) * 2005-01-13 2011-11-15 Univ Keio Genmarker und dessen verwendung
EP2327429B1 (en) 2005-03-23 2014-09-17 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20070043033A1 (en) 2005-06-01 2007-02-22 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
CN1876822B (zh) * 2005-06-06 2010-05-12 äøŠęµ·åø‚农čÆē ”ē©¶ę‰€ ä»–å…‹čŽ«åøēš„äŗ§ē”ŸčŒę Ŗ及ē”Ÿäŗ§ę–¹ę³•
WO2007013017A1 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited A process for purification of macrolides
ITMI20051549A1 (it) * 2005-08-05 2007-02-06 Antibioticos Spa Purificazione del tacrolimus su supporti dimorigine vegetale
WO2007029082A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited An improved fermentation process for preparing ascomycin
US20080318289A1 (en) * 2005-10-05 2008-12-25 Parveen Kumar Fermentation Processes for the Preparation of Tacrolimus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
RU2008122978A (ru) 2005-11-09 2009-12-20 ŠšŠ¾Š¼Š±ŠøŠ½Š°Ń‚Š¾Ń€Šŗс, Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) Š”ŠæŠ¾ŃŠ¾Š±Ń‹, ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Šø Š½Š°Š±Š¾Ń€Ń‹ Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Š¼ŠµŠ“ŠøцŠøŠ½ŃŠŗŠøх сŠ¾ŃŃ‚Š¾ŃŠ½ŠøŠ¹
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
DE602007006601D1 (de) * 2006-03-15 2010-07-01 Teva Gyogyszergyar Zartkoeruee Verfahren zur reinigung von tacrolimus
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2008026781A1 (en) 2006-08-31 2008-03-06 Astellas Pharma Inc. Reverse targeting lipid vesicle
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008057511A2 (en) * 2006-11-06 2008-05-15 Teva GyĆ³gyszergyĆ”r ZĆ”rtkƶrĆ¼en MĆ¼kƶdƶ RĆ©szvĆ©nytĆ”rsasĆ”g Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
EP2124898B1 (en) 2007-01-10 2013-08-14 Board of Regents, The University of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
BRPI0808653A2 (pt) 2007-03-09 2014-08-19 Univ Michigan ComposiƧƵes e mƩtodos referindo-se a novos compostos e alvos dos mesmos.
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
KR100891313B1 (ko) * 2007-08-17 2009-03-31 (ģ£¼) ģ œė…øķ… ė‹“ģ²“ė”œ ģž‘ģš©ķ•˜ėŠ” ķ”ģ°©ģ„± ģˆ˜ģ§€ģ˜ ģ œź³µģ— ģ˜ķ•œ ķŠøė¦¬ģ‚¬ģ“ķ“ė”œķ™”ķ•©ė¬¼ģ˜ ģƒģ‚° ė° ģ¶”ģ¶œ ė°©ė²•
AU2008298870C1 (en) 2007-09-14 2014-10-09 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
MX2010004857A (es) 2007-11-06 2010-07-28 Univ Michigan Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel.
CA2711765A1 (en) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
KR101003042B1 (ko) 2008-03-17 2010-12-21 ģ¢…ź·¼ė‹¹ė°”ģ“ģ˜¤ ģ£¼ģ‹ķšŒģ‚¬ ź³ ģˆœė„ ķƒ€ķ¬ė”œė¦¬ė¬“ģŠ¤ģ˜ ģ •ģ œ ė°©ė²•
EP2262892A4 (en) * 2008-04-08 2011-09-21 Amyris Biotechnologies Inc EXPRESSION OF HETEROLOGOUS SEQUENCES
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
EP2352724B1 (en) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryl guanidine f1f0-atpase inhibitors and their medical use
KR100910165B1 (ko) 2008-09-18 2009-07-30 (ģ£¼) ģ œė…øķ… ģ€ ģ“ģ˜Ø ģš©ģ•” ģ¶”ģ¶œģ„ ģ“ģš©ķ•œ ė¶ˆķ¬ķ™” ģ•Œķ‚¬źø°ė„¼ ź°€ģ§„ ė½ķ†¤ ķ™”ķ•©ė¬¼ ģ •ģ œė°©ė²•
WO2010041684A1 (ja) * 2008-10-08 2010-04-15 高ē”°č£½č–¬ę Ŗ式会ē¤¾ ć‚æć‚Æ惭ćƒŖćƒ ć‚¹å¤–ē”Ø剤
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc AnƔlogos de nucleosƭdeo
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleĆ³sidos
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
CN101712686B (zh) * 2009-06-22 2012-08-29 鲁南制čÆé›†å›¢č‚”ä»½ęœ‰é™å…¬åø äø€ē§å‘é…µę¶²äø­ä»–å…‹čŽ«åøēš„分ē¦»ēŗÆåŒ–ę–¹ę³•
EP2272963A1 (en) * 2009-07-09 2011-01-12 LEK Pharmaceuticals d.d. Process for Preparation of Tacrolimus
WO2011035124A1 (en) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
CA2915237C (en) 2009-11-17 2017-10-10 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 悶 ćƒŖćƒ¼ć‚øć‚§ćƒ³ćƒ„ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ćƒŸć‚·ć‚¬ćƒ³ ę²»ē™‚ē‰¹ę€§ć‚’ęœ‰ć™ć‚‹ļ¼‘ļ¼Œļ¼”āˆ’ćƒ™ćƒ³ć‚¾ć‚øć‚¢ć‚¼ćƒ”ćƒ³āˆ’ļ¼’ļ¼Œļ¼•āˆ’ć‚øć‚Ŗćƒ³ćŠć‚ˆć³é–¢é€£åŒ–åˆē‰©
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
TWI510238B (zh) 2010-02-17 2015-12-01 Lifecycle Pharma As ē©©å®šåŒ–ä»–å…‹čŽ«åøļ¼ˆļ½”ļ½ļ½ƒļ½’ļ½ļ½Œļ½‰ļ½ļ½•ļ½“ļ¼‰ēµ„合ē‰©
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
KR101261131B1 (ko) 2010-08-24 2013-05-06 ģ“ķ™”ģ—¬ģžėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø ģ‹ ź·œ ķƒ€ķ¬ė”¤ė¦¬ė¬“ģŠ¤ ģœ ė„ģ²“, ģƒźø° ģœ ė„ģ²“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ģ‹ ź²½ ė³“ķ˜øģš© ģ”°ģ„±ė¬¼, ģƒźø° ģœ ė„ģ²“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ ģ–µģ œģš© ģ”°ģ„±ė¬¼, ģƒźø° ģœ ė„ģ²“ģ˜ ģƒģ‚° ė°©ė²• ė° ģƒźø° ģœ ė„ģ²“ģ˜ ģƒģ‚° ź· ģ£¼
MA34586B1 (fr) 2010-08-25 2013-10-02 Medis Lab Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
US10117411B2 (en) 2010-10-06 2018-11-06 Dow Agrosciences Llc Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizaƧƵes
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd PrĆ³-fĆ”rmacos de fumaratos e seu uso no tratamento de vĆ”rias doenƧas
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN104650112B (zh) * 2013-11-18 2018-07-31 å±±äøœę–°ę—¶ä»£čÆäøšęœ‰é™å…¬åø ä»–å…‹čŽ«åø8-äø™åŸŗē±»ä¼¼ē‰©ēš„åˆ¶å¤‡ę–¹ę³•
UY35927A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmƔtica del maƭz (cms), marcadores moleculares y sus usos?.
EP3094324A4 (en) 2014-01-13 2017-02-22 Amplyx Pharmaceuticals, Inc. Antifungal compounds
CA2935167C (en) 2014-01-16 2022-02-22 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
KR101694879B1 (ko) * 2014-08-01 2017-01-12 ģ£¼ģ‹ķšŒģ‚¬ ģøķŠøė” ė°”ģ“ģ˜¤ķ…Œķ¬ė†€ė”œģ§€ ė©“ģ—­ģ–µģ œķ™œģ„± ģ—†ģ“ ģ‹ ź²½ģž¬ģƒķ™œģ„±ģ“ ģœ ģ§€ė˜ėŠ” fk506 ģœ ė„ģ²“ ė° ź·øģ˜ ģš©ė„
US10143682B2 (en) 2014-10-28 2018-12-04 Koushi Yamaguchi Medicine for improving state of pregnancy, and use thereof
KR102706357B1 (ko) 2015-08-19 2024-09-11 ė¹„ė²„ģŠ¤ ģøķ¬. ģ œģ•½ ģ œģ œ
CN109069621B (zh) 2015-09-04 2022-09-06 ę™®é‡ŒēŽ›ę‰˜ę™®åŒ»ē–—č‚”ä»½ęœ‰é™å…¬åø äŗŗęŗåŒ–ꊗ-cd40ęŠ—ä½“åŠå…¶ē”Ø途
CN106074367A (zh) * 2016-07-20 2016-11-09 äø­å±±å¤§å­¦äø­å±±ēœ¼ē§‘äø­åæƒ å«fk506ē±»åŒ–合ē‰©/fkbp蛋ē™½äŗŒčšä½“ēš„čÆē‰©ē»„合ē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•
CN108384819B (zh) * 2017-02-03 2021-06-25 äøŠęµ·åŒ»čÆå·„äøšē ”ē©¶é™¢ äø€ē§ē”ØäŗŽå‘é…µä»–å…‹čŽ«åøēš„培养åŸŗä»„åŠå‘é…µę–¹ę³•
RU2686779C1 (ru) * 2018-07-26 2019-04-30 ŠžŠ±Ń‰ŠµŃŃ‚Š²Š¾ с Š¾Š³Ń€Š°Š½ŠøчŠµŠ½Š½Š¾Š¹ Š¾Ń‚Š²ŠµŃ‚стŠ²ŠµŠ½Š½Š¾ŃŃ‚ŃŒŃŽ "Š˜Š·Š²Š°Ń€ŠøŠ½Š¾ Š¤Š°Ń€Š¼Š°" ŠØтŠ°Š¼Š¼ streptomyces tsukubensis - ŠæрŠ¾Š“уцŠµŠ½Ń‚ тŠ°ŠŗрŠ¾Š»ŠøŠ¼ŃƒŃŠ° Šø сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя тŠ°ŠŗрŠ¾Š»ŠøŠ¼ŃƒŃŠ°
CA3108863A1 (en) 2018-08-10 2020-02-13 Koushi Yamaguchi Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
EP3930713B1 (en) 2018-12-04 2025-05-28 Ilko IlaƧ Sanayi Ve Ticaret Anonim Sirketi Stable tacrolimus ointment formulation for topical treatment of skin conditions
JPWO2020129348A1 (ja) 2018-12-18 2021-11-04 ę™ƒå² 山口 äøå¦Šćƒ»äøč‚²ē—‡ć¾ćŸćÆ妊åØ ēŠ¶ę…‹ć‚’ę”¹å–„ć™ć‚‹ćŸć‚ć®č–¬å‰¤
WO2020163594A1 (en) * 2019-02-07 2020-08-13 The Regents Of The University Of California Immunophilin binding agents and uses thereof
GR1009790B (el) 2019-03-20 2020-08-03 Ī¦Ī±ĻĪ¼Ī±Ļ„ĪµĪ½ Ī‘.Ī’.Ī•.Ī•. Ī£ĪŗĪµĻ…Ī±ĻƒĪ¼Ī± Ļ€Ī±ĻĪ±Ļ„ĪµĻ„Ī±Ī¼ĪµĪ½Ī·Ļ‚ Ī±Ļ€ĪæĪ“ĪµĻƒĪ¼ĪµĻ…ĻƒĪ·Ļ‚ Ļ€ĪæĻ… Ļ€ĪµĻĪ¹Ī»Ī±Ī¼Ī²Ī±Ī½ĪµĪ¹ Ļ„Ī±ĪŗĻĪæĪ»Ī¹Ī¼ĪæĻ…Ļ‚
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (13)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
JPS54110000A (en) * 1978-02-17 1979-08-29 Kaken Pharmaceut Co Ltd Novel streptovaricin c derivative
US4309504A (en) * 1980-01-28 1982-01-05 Eli Lilly And Company Process for preparing narasin
US4654334A (en) * 1980-10-08 1987-03-31 International Minerals & Chemical Corp. Manganese-containing antibiotic agents
US4415669A (en) * 1981-12-07 1983-11-15 Merck & Co., Inc. Substance and process for its production
US4390546A (en) * 1981-12-07 1983-06-28 Merck & Co., Inc. Antiparasitic macrolide from a strain of Streptomyces hygroscopicus
US4510317A (en) * 1983-07-28 1985-04-09 Hoffmann-La Roche Inc. Antibiotic X-14934A
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (pt) * 1987-11-09 1991-05-31 Sandoz Ag
US5956352A (en) * 1992-04-24 1999-09-21 Digital Equipment Corporation Adjustable filter for error detecting and correcting system

Also Published As

Publication number Publication date
JP2828091B2 (ja) 1998-11-25
IE62865B1 (en) 1995-03-08
HUT41842A (en) 1987-05-28
KR930010705B1 (ko) 1993-11-08
PT81589B (pt) 1987-10-20
CN1013687B (zh) 1991-08-28
DK556285D0 (da) 1985-11-29
JP2976966B2 (ja) 1999-11-10
FI854731A0 (fi) 1985-11-29
US5565559A (en) 1996-10-15
NZ214407A (en) 1989-11-28
IE852971L (en) 1986-06-03
NO168372B (no) 1991-11-04
GR852904B (pt) 1986-04-01
MX9202943A (es) 1992-06-30
FI864527L (fi) 1986-11-07
CY1912A (en) 1985-11-30
US4929611A (en) 1990-05-29
DE3587806D1 (de) 1994-06-01
US5624842A (en) 1997-04-29
ATE104984T1 (de) 1994-05-15
HU195250B (en) 1988-04-28
DE3587806T2 (de) 1994-08-25
US6482845B1 (en) 2002-11-19
IL77222A (en) 1991-06-10
FI854731L (fi) 1986-06-04
KR930010707B1 (ko) 1993-11-08
ES549478A0 (es) 1987-04-16
US20040029908A1 (en) 2004-02-12
DK556285A (da) 1986-06-04
NL960023I1 (nl) 1996-12-02
ES8705038A1 (es) 1987-04-16
US4956352A (en) 1990-09-11
JP2746134B2 (ja) 1998-04-28
JPH07224066A (ja) 1995-08-22
NL960023I2 (nl) 1997-06-02
US5830717A (en) 1998-11-03
US20030170831A1 (en) 2003-09-11
JPH0346445B2 (pt) 1991-07-16
IL92345A (en) 1991-06-10
JPH0372483A (ja) 1991-03-27
NO168372C (no) 1992-02-12
CN85109492A (zh) 1986-06-10
FI87803C (fi) 1993-02-25
DK169550B1 (da) 1994-11-28
KR930010706B1 (ko) 1993-11-08
FI87803B (fi) 1992-11-13
EP0184162A2 (en) 1986-06-11
US6201005B1 (en) 2001-03-13
JPH0372484A (ja) 1991-03-27
US5110811A (en) 1992-05-05
JPH1067783A (ja) 1998-03-10
US20050124646A1 (en) 2005-06-09
AU5059685A (en) 1986-06-12
US5496727A (en) 1996-03-05
US6028097A (en) 2000-02-22
KR860004918A (ko) 1986-07-16
HK18596A (en) 1996-02-09
JPH0720970B2 (ja) 1995-03-08
JP3211891B2 (ja) 2001-09-25
EP0184162B1 (en) 1994-04-27
JPH1112281A (ja) 1999-01-19
KR930010708B1 (ko) 1993-11-08
JPH11343294A (ja) 1999-12-14
US20030229115A1 (en) 2003-12-11
CA1338491C (en) 1996-07-30
FI85977B (fi) 1992-03-13
NO854833L (no) 1986-06-04
KR930010704B1 (ko) 1993-11-08
AU592067B2 (en) 1990-01-04
DE19575026I2 (de) 2002-03-28
FI864527A0 (fi) 1986-11-07
EP0184162A3 (en) 1989-02-08
US4894366A (en) 1990-01-16
FI85977C (fi) 1992-06-25
LU90317I2 (fr) 1999-01-11

Similar Documents

Publication Publication Date Title
PT81589A (en) Process for the preparation of tricyclo compounds useful for treating and preventing resistence by transplantation and other diseases
DE3571436D1 (en) New pharmaceutical compositions having anti-psychotic properties
PT78751B (en) Preparation process of 2-pyrimidinyl-1-piperazine derivatives and medicines containing them
ES8400409A1 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
DE3571982D1 (en) Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds
IE811217L (en) Para-substituted 3-phenoxy-1-alkylaminopropan-2-ols havingĀ¹beta receptor blocking properties
ZA848655B (en) 11-substituted 5h,11h-pyrrolo(2,1-c)(1,4)benzoxazepines,a process for their preparation and their use as medicaments
DE3268008D1 (en) A new acaricidal composition, processes for its production and its use
ATE38029T1 (de) Benz-trisubstituierte 2-aminotetraline.
IL110865A (en) Difluoro statone analogs process for their preparation and pharmaceutical compositions containing them
JO1711B1 (en) Therapeutic agents